Key Points
- Bicara Therapeutics COO Ryan Cohlhepp sold 12,500 shares on May 15 at an average price of $20.29, worth about $253,625. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The transaction reduced Cohlhepp’s direct holdings to 191,641 shares, a 6.12% decrease in his position. He has also sold shares several times in recent months.
- BCAX opened at $19.29 and has traded between $7.80 and $24.25 over the past year. The company recently reported a quarterly loss of $0.93 per share, missing Wall Street estimates, while analysts currently hold a Moderate Buy consensus with a $30.27 price target.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the company's stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.29, for a total value of $253,625.00. Following the transaction, the chief operating officer directly owned 191,641 shares in the company, valued at $3,888,395.89. This represents a 6.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Cohlhepp also recently made the following trade(s):
- On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.01, for a total value of $287,625.00.
- On Monday, March 16th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.66, for a total value of $245,750.00.
- On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.16, for a total value of $315,838.72.
Bicara Therapeutics Price Performance
Shares of BCAX stock opened at $19.29 on Tuesday. The business's fifty day moving average price is $21.03 and its 200 day moving average price is $18.21. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $24.25. The firm has a market capitalization of $1.27 billion, a PE ratio of -6.94 and a beta of -0.57.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.21). Equities research analysts expect that Bicara Therapeutics Inc. will post -3.37 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Bicara Therapeutics
Large investors have recently added to or reduced their stakes in the business. Cantor Fitzgerald L. P. purchased a new position in Bicara Therapeutics during the third quarter worth about $1,579,000. Bleakley Financial Group LLC purchased a new position in Bicara Therapeutics during the third quarter worth about $481,000. Nan Fung Trinity HK Ltd. lifted its position in Bicara Therapeutics by 12.2% during the third quarter. Nan Fung Trinity HK Ltd. now owns 384,885 shares of the company's stock worth $6,077,000 after buying an additional 42,000 shares during the period. Atle Fund Management AB lifted its position in Bicara Therapeutics by 38.3% during the third quarter. Atle Fund Management AB now owns 203,755 shares of the company's stock worth $3,217,000 after buying an additional 56,375 shares during the period. Finally, Cinctive Capital Management LP purchased a new position in Bicara Therapeutics during the third quarter worth about $661,000.
Analyst Upgrades and Downgrades
Several research firms have weighed in on BCAX. Citigroup began coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued an "outperform" rating on the stock. Guggenheim began coverage on Bicara Therapeutics in a report on Monday, May 11th. They issued a "buy" rating and a $42.00 target price on the stock. HC Wainwright upped their target price on Bicara Therapeutics from $40.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Wednesday, April 8th. Finally, Wall Street Zen lowered Bicara Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.27.
Check Out Our Latest Analysis on Bicara Therapeutics
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
